ARCHIMED Pharma Services has successfully spun off SuanNutra, a leading nutraceutical ingredients company, to Carbyne Equity Partners as part of a strategic growth initiative.
Target Information
SuanNutra, a subsidiary of Suanfarma, has emerged as a globally recognized leader in the nutraceutical ingredients sector. Representing approximately 25% of Suanfarma's overall sales, SuanNutra has evolved significantly since its inception, establishing a reputation for quality and innovation in the nutraceuticals market. Through strategic management and investment, SuanNutra has transitioned from a corporate division to a scalable, standalone business, positioning itself for continued growth.
Founded in 1993 and headquartered in Madrid, Suanfarma has seen substantial development under the ownership of ARCHIMED’s MED Platform I fund, which raised €1 billion in 2021 and boasts a strong performance ranking among global buyout funds. The evolution of SuanNutra is a testament to ARCHIMED's commitment to innovation and strategic growth within the healthcare sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The nutraceuticals industry has experienced substantial growth, driven by increasing consumer awareness regarding health and wellness. In Spain, a strong emphasis on dietary supplements and functional food
Similar Deals
Miura Partners → Centro Psicosanitario Galiani and Orientak
2025
Miura Partners → Saesco Medical
2025
Investor group advised by Rigeto Unternehmerkapital → Leaseir Medical Light S.L.
2023
Carbyne Equity Partners
invested in
SuanNutra
in 2025
in a Other Private Equity deal